J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 19.06 CNY -0.88% Market Closed
Market Cap: ¥15.2B

EV/FCFF

24.1
Current
4%
Cheaper
vs 3-y average of 25.2

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
24.1
=
Enterprise Value
¥12.7B
/
Free Cash Flow to Firm
¥578.7m

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
24.1
=
Enterprise Value
¥12.7B
/
Free Cash Flow to Firm
¥578.7m

Valuation Scenarios

Jafron Biomedical Co Ltd is trading below its 3-year average

If EV/FCFF returns to its 3-Year Average (25.2), the stock would be worth ¥19.92 (5% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+19%
Average Upside
15%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 24.1 ¥19.06
0%
3-Year Average 25.2 ¥19.92
+5%
5-Year Average 28.6 ¥22.61
+19%
Industry Average 28.7 ¥22.7
+19%
Country Average 28.8 ¥22.74
+19%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
CN
Jafron Biomedical Co Ltd
SZSE:300529
15.2B CNY 24.1 31.6
US
Intuitive Surgical Inc
NASDAQ:ISRG
161.2B USD 62.5 56.6
US
Abbott Laboratories
NYSE:ABT
158.6B USD 21.5 25.2
US
Stryker Corp
NYSE:SYK
120.5B USD 30.9 37.3
IE
Medtronic PLC
NYSE:MDT
101.9B USD 22.7 22.4
US
Boston Scientific Corp
NYSE:BSX
84.8B USD 25.9 24
US
Edwards Lifesciences Corp
NYSE:EW
47.2B USD 33.5 44.1
DE
Siemens Healthineers AG
XETRA:SHL
39.3B EUR 20.9 18.6
US
IDEXX Laboratories Inc
NASDAQ:IDXX
44.1B USD 43.1 42.1
US
Becton Dickinson and Co
NYSE:BDX
41.4B USD 22.1 24
US
Resmed Inc
NYSE:RMD
30.9B USD 16.9 21

Market Distribution

In line with most companies in China
Percentile
45th
Based on 4 731 companies
45th percentile
24.1
Low
0 — 14.5
Typical Range
14.5 — 57
High
57 —
Distribution Statistics
China
Min 0
30th Percentile 14.5
Median 28.8
70th Percentile 57
Max 307 555.7

Jafron Biomedical Co Ltd
Glance View

Market Cap
15.2B CNY
Industry
Health Care

In the heart of China's bustling Guangdong province, Jafron Biomedical Co., Ltd. has carved a distinguished niche in the world of biomedicine since its inception. This innovative company, recognized as a leader in the hemoperfusion field, has built its reputation on a foundation of pioneering blood purification technologies. By developing and manufacturing an array of hemoperfusion devices, Jafron offers critical solutions that aid in the removal of toxins from the bloodstream, thus improving outcomes for patients suffering from various systemic toxic reactions and kidney-related disorders. Their state-of-the-art hemoperfusion cartridges, meticulously designed for efficiency, are instrumental in managing and treating conditions such as chronic kidney disease and liver dysfunction. This relentless pursuit of quality is bolstered by a dedicated research division that harmonizes clinical insights with scientific innovation, ensuring Jafron stays at the forefront of clinical demand. Jafron Biomedical thrives on a robust business model that fuses direct sales with an expansive network of partnerships. This dual approach not only amplifies their market reach but also enables the company to establish solid footholds in key domestic and international markets. By collaborating with healthcare institutions and medical device distributors, Jafron ensures its products deliver critical health solutions to a broad clientele. The revenue streams are mainly anchored in the sales of its hemoperfusion products and through strategic expansions in emerging markets. As global health standards evolve and the demand for advanced medical solutions expands, Jafron is positioned to sustain its growth momentum by continually innovating in response to the global demand for efficient blood purification therapies. Through these methods, Jafron not only augments its economic footprint but also underscores its commitment to enhancing global healthcare standards.

Intrinsic Value
15.8 CNY
Overvaluation 17%
Intrinsic Value
Price ¥19.06
J
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett